Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Movers and Shakers

- PMLiVE

Solid Q1 results lift Pfizer as it waits for pipeline boost

Shares rose almost 2% in the wake of the presentation

- PMLiVE

Pfizer gets EU nod for Tagrisso rival Vizimpro

Five year survival still only 12%

- PMLiVE

Sangamo surges on data for haemophilia A gene therapy

After recent setbacks, news lifts shares

- PMLiVE

Pfizer hedges bets on gene therapy deal

Company not splashing out like Roche's Spark purchase

- PMLiVE

NICE partially clears Darzalex combo in blood cancer

Approved in second-line use under  CDF

- PMLiVE

UK Biobank generates “largest open access resource of exome data”

Around 50,000 de-identifed genetic profiles available for research

“Brexit has been a catalyst for UK clinical research… it’s turbocharged change”

The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?

- PMLiVE

Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry

Will be joined by chief commercial officer Stuart Arbuckle

- PMLiVE

UK launches National Genomic Healthcare strategy

New initiative unveiled to coincide with Rare Disease Day

Eli Lilly HQ

Lilly, Pfizer say NGF drug works in back pain too

Tanezumab was able to show a statistically significant improvement in pain

- PMLiVE

UCB signs research deal with King’s College London

Company and academic researchers to share one facility

- PMLiVE

Bicycle Therapeutics to tackle AMR with government funding

Biotech to discover new class of antibacterial agents

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links